Standout Papers
- Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening (2020)
- AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (2023)
- The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (2024)
- American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings (2022)
Immediate Impact
8 from Science/Nature 71 standout
Citing Papers
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
2024 Standout
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
2024 Standout
Works of Diana Barb being referenced
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes
2019
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Diana Barb | 2527 | 1396 | 505 | 873 | 31 | 3.2k | |
| Claire Z. Larter | 3002 | 1292 | 583 | 913 | 24 | 3.6k | |
| Arian Afendy | 2622 | 1240 | 456 | 1149 | 33 | 3.2k | |
| Dawn M. Torres | 3289 | 1453 | 472 | 1458 | 36 | 3.7k | |
| Elena Buzzetti | 2245 | 955 | 291 | 604 | 38 | 2.8k | |
| David Ka‐Wai Yeung | 2021 | 907 | 370 | 720 | 21 | 2.6k | |
| Carol Sargeant | 3453 | 1625 | 835 | 1488 | 17 | 4.1k | |
| Luis Calzadilla Bertot | 3038 | 1409 | 541 | 1550 | 36 | 3.4k | |
| Raffaela Rametta | 2598 | 1173 | 378 | 881 | 68 | 3.6k | |
| M. Marietti | 3813 | 1554 | 574 | 1474 | 17 | 4.4k | |
| Mara Brizi | 2966 | 1711 | 538 | 724 | 15 | 3.6k |
All Works
Login with ORCID to disown or claim papers
Loading papers...